Effects of penbutolol on plasma atrial natriuretic peptide and antidiuretic hormone levels before and after exercise : a double-blind comparison against placebo

A double-blind crossover trial was carried out in 7 healthy male volunteers to investigate the effects of penbutolol and a placebo on plasma atrial natriuretic peptide (ANP) and antidiuretic hormone (ADH) levels before and after exercise. Each subject underwent several bicycle ergometric exercises l...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC). - 1995. - 5(1989), 5 vom: 26., Seite 320-8
1. Verfasser: Verho, M (VerfasserIn)
Weitere Verfasser: Färber, G, Kirsten, R, Nelson, K
Format: Aufsatz
Sprache:English
Veröffentlicht: 1989
Zugriff auf das übergeordnete Werk:Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC)
Schlagworte:Clinical Trial Comparative Study Controlled Clinical Trial Journal Article Randomized Controlled Trial Chlorides Propanolamines Vasopressins 11000-17-2 Penbutolol mehr... 78W62V43DY Atrial Natriuretic Factor 85637-73-6 Sodium 9NEZ333N27 Creatinine AYI8EX34EU
LEADER 01000naa a22002652 4500
001 NLM025077317
003 DE-627
005 20231221094722.0
007 tu
008 231221s1989 xx ||||| 00| ||eng c
028 5 2 |a pubmed24n0084.xml 
035 |a (DE-627)NLM025077317 
035 |a (NLM)2526341 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Verho, M  |e verfasserin  |4 aut 
245 1 0 |a Effects of penbutolol on plasma atrial natriuretic peptide and antidiuretic hormone levels before and after exercise  |b a double-blind comparison against placebo 
264 1 |c 1989 
336 |a Text  |b txt  |2 rdacontent 
337 |a ohne Hilfsmittel zu benutzen  |b n  |2 rdamedia 
338 |a Band  |b nc  |2 rdacarrier 
500 |a Date Completed 25.08.1989 
500 |a Date Revised 21.11.2013 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a A double-blind crossover trial was carried out in 7 healthy male volunteers to investigate the effects of penbutolol and a placebo on plasma atrial natriuretic peptide (ANP) and antidiuretic hormone (ADH) levels before and after exercise. Each subject underwent several bicycle ergometric exercises lasting 6 min before and after the application of test medications. Ergometric exercises were performed before medication, and at 2, 5, 9 and 24 hours after medication. Blood samples for ANP and ADH levels were drawn before, after 15 min, after 2 hours (immediately after ergometry) and 5, 7, 9, and 24 hours after medication (immediately before ergometry). Urine was collected as follows: -2 to 0, 0 to 2, 2 to 4, 4 to 7, 7 to 14 and 14 to 24 hours after medication, and the volume as well as sodium excretion were documented. Penbutolol caused suppression of the exercise-induced increase in ANP. The 2 to 4 hour fractional sodium excretion was significantly decreased from 12.1 +/- 4.9 mmol/fraction after placebo treatment to 7.8 +/- 3.0 mmol/fraction after penbutolol application (p less than 0.03). There were no differences in the urinary outputs between penbutolol and placebo until 4 hours after medication, but penbutolol caused the total urinary output to increase from 1390 +/- 388 ml/24 hr during placebo treatment to 1725 +/- 549 ml/24 hr (p less than 0.02) due to the last collection fraction. Blood pressure and pulse rate both decreased during exercise after penbutolol. As opposed to the suppressing influence of penbutolol on ANP, ADH plasma levels were increased after exercise.(ABSTRACT TRUNCATED AT 250 WORDS) 
650 4 |a Clinical Trial 
650 4 |a Comparative Study 
650 4 |a Controlled Clinical Trial 
650 4 |a Journal Article 
650 4 |a Randomized Controlled Trial 
650 7 |a Chlorides  |2 NLM 
650 7 |a Propanolamines  |2 NLM 
650 7 |a Vasopressins  |2 NLM 
650 7 |a 11000-17-2  |2 NLM 
650 7 |a Penbutolol  |2 NLM 
650 7 |a 78W62V43DY  |2 NLM 
650 7 |a Atrial Natriuretic Factor  |2 NLM 
650 7 |a 85637-73-6  |2 NLM 
650 7 |a Sodium  |2 NLM 
650 7 |a 9NEZ333N27  |2 NLM 
650 7 |a Creatinine  |2 NLM 
650 7 |a AYI8EX34EU  |2 NLM 
700 1 |a Färber, G  |e verfasserin  |4 aut 
700 1 |a Kirsten, R  |e verfasserin  |4 aut 
700 1 |a Nelson, K  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC)  |d 1995  |g 5(1989), 5 vom: 26., Seite 320-8  |w (DE-627)NLM023961570 
773 1 8 |g volume:5  |g year:1989  |g number:5  |g day:26  |g pages:320-8 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_22 
912 |a GBV_ILN_24 
912 |a GBV_ILN_31 
912 |a GBV_ILN_39 
912 |a GBV_ILN_40 
912 |a GBV_ILN_72 
912 |a GBV_ILN_120 
912 |a GBV_ILN_121 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 5  |j 1989  |e 5  |b 26  |h 320-8